WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Gilead and Merck's latest trial success and flop — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 13 fonti

Gilead and Merck's latest trial success and flop

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

Raccontata da

thehindubusinessline.com

independent.co.uk

morningstar.com

hindustantimes.com

newsbytesapp.com

malaymail.com+1 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mese fa

Gilead and Merck's latest trial success and flop

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

Timeline cronologica

lunedì 8 giugno 2026·statnews.com
Novo underwhelmed by drug it once fought Pfizer for
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
martedì 9 giugno 2026·cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

thisdaylive.com

1 mese fa

GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion

GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion

Leggi questa versione → originale

endpoints.news1 mese fa

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.

Leggi questa versione → originale

cryptobriefing.com1 mese fa

GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business

GSK is acquiring Nuvalent for $10.6 billion in cash, gaining three late-stage lung cancer therapies including two drugs already under FDA review.

Leggi questa versione → originale

newsbytesapp.com1 mese fa

GSK buys US biopharma company Nuvalent for $10.6B

Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.

Leggi questa versione → originale

cityam.com1 mese fa

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

Leggi questa versione → originale

martedì 9 giugno 2026·

thehindubusinessline.com

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion

GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.

martedì 9 giugno 2026·

cityam.com

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

martedì 9 giugno 2026·

endpoints.news

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.

martedì 9 giugno 2026·

statnews.com

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

martedì 9 giugno 2026·

independent.co.uk

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

martedì 9 giugno 2026·

morningstar.com

Dow Jones Top Company Headlines at 3 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | University ...

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

martedì 9 giugno 2026·

hindustantimes.com

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News

martedì 9 giugno 2026·

morningstar.com

Dow Jones Top Company Headlines at 5 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | University ...

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

martedì 9 giugno 2026·

barrons.com

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.

martedì 9 giugno 2026·

benzinga.com

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.

martedì 9 giugno 2026·

morningstar.com

Dow Jones Top Company Headlines at 7 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | University ...

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

martedì 9 giugno 2026·

newsbytesapp.com

GSK buys US biopharma company Nuvalent for $10.6B

Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.

martedì 9 giugno 2026·

malaymail.com

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...

martedì 9 giugno 2026·

morningstar.com

Dow Jones Top Company Headlines at 9 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

martedì 9 giugno 2026·

investors.com

Small Biotech Catapults To Record High On $10.6 Billion Deal

GSK made an all-cash bid to buy the small cancer-focused biotech company for $10.6 billion.

martedì 9 giugno 2026·

statnews.com

Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more

GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology

martedì 9 giugno 2026·

statnews.com

Gilead and Merck's latest trial success and flop

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

martedì 9 giugno 2026·

morningstar.com

Dow Jones Top Company Headlines at 11 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push